1. Home
  2. SILO vs GTBP Comparison

SILO vs GTBP Comparison

Compare SILO & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SILO
  • GTBP
  • Stock Information
  • Founded
  • SILO 2010
  • GTBP 1965
  • Country
  • SILO United States
  • GTBP United States
  • Employees
  • SILO N/A
  • GTBP N/A
  • Industry
  • SILO Apparel
  • GTBP Biotechnology: Pharmaceutical Preparations
  • Sector
  • SILO Consumer Discretionary
  • GTBP Health Care
  • Exchange
  • SILO Nasdaq
  • GTBP Nasdaq
  • Market Cap
  • SILO 8.8M
  • GTBP 4.9M
  • IPO Year
  • SILO N/A
  • GTBP N/A
  • Fundamental
  • Price
  • SILO $1.65
  • GTBP $2.15
  • Analyst Decision
  • SILO
  • GTBP Strong Buy
  • Analyst Count
  • SILO 0
  • GTBP 1
  • Target Price
  • SILO N/A
  • GTBP $11.00
  • AVG Volume (30 Days)
  • SILO 803.7K
  • GTBP 238.5K
  • Earning Date
  • SILO 02-18-2025
  • GTBP 03-25-2025
  • Dividend Yield
  • SILO N/A
  • GTBP N/A
  • EPS Growth
  • SILO N/A
  • GTBP N/A
  • EPS
  • SILO N/A
  • GTBP N/A
  • Revenue
  • SILO $72,102.00
  • GTBP N/A
  • Revenue This Year
  • SILO $1.86
  • GTBP N/A
  • Revenue Next Year
  • SILO N/A
  • GTBP N/A
  • P/E Ratio
  • SILO N/A
  • GTBP N/A
  • Revenue Growth
  • SILO N/A
  • GTBP N/A
  • 52 Week Low
  • SILO $0.77
  • GTBP $1.72
  • 52 Week High
  • SILO $4.50
  • GTBP $10.66
  • Technical
  • Relative Strength Index (RSI)
  • SILO 52.57
  • GTBP 42.94
  • Support Level
  • SILO $1.56
  • GTBP $2.10
  • Resistance Level
  • SILO $1.89
  • GTBP $2.39
  • Average True Range (ATR)
  • SILO 0.19
  • GTBP 0.21
  • MACD
  • SILO -0.05
  • GTBP 0.01
  • Stochastic Oscillator
  • SILO 27.12
  • GTBP 36.00

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: